Lakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT ticker

Bitget2026/09/21 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lakewood-Amedex Biotherapeutics shifted its stock listing to the Nasdaq Capital Market under ticker LABT on April 23, 2026.
The listing followed a $7.5 million private placement of Series C Convertible Preferred Stock, aimed at supporting clinical development.
Earlier preferred stock and convertible notes converted into common stock in connection with the Nasdaq listing, simplifying the capital structure.
A Sept. 18 registration statement covered up to 4,512,400 common shares issuable from remaining Series C conversions, enabling staged sales.
Shareholders vote Sept. 22 on raising authorized common shares to 100 million, with reverse-split authority up to 1-for-20 if needed for Nasdaq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210802PR_NEWS_USPR_____NY52203) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT ticker

You may also like

Crypto prices